European pharma entry into Eurasia: why local partners matter

A growing market with regulatory challenges

The pharmaceutical market in Eurasia is a major opportunity for European companies. In Uzbekistan and Kazakhstan, more than 50% of medicines are imported, creating constant demand for high-quality and innovative products. Yet, entering this market is complex. Registration, certification, and tendering procedures vary by country and may take between 6 and 18 months.

Why information and a local partner are key

For European pharma firms, having precise information and a trusted local partner is critical. This enables them to:

• Streamline registration and certification.

• Access public procurement programs.

• Build reliable distribution networks.

• Manage logistics for sensitive products.

• Leverage financing and insurance mechanisms.

Workshop in Tashkent: clear answers from experts

All these issues will be addressed by European specialists at the upcoming workshop organized by ACIR Southern Europe:

📍 The Writer’s Room Club, Tashkent
📅 September 30
⏰ 17:00

Experts from Southern Europe will share strategies, case studies, and practical solutions to support companies entering Eurasian markets.